We serve Chemical Name:2-Bromo-4-tert-butylbenzaldehyde CAS:246139-77-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Bromo-4-tert-butylbenzaldehyde
CAS.NO:246139-77-5
Synonyms:2-bromo-4-t-butylbenzaldehyde;2-bromo-4-tert-butylbenzaldehyde;2-Bromo-4-tert-butyl-benzaldehyde;Benzaldehyde, 2-bromo-4-(1,1-dimethylethyl)-;2-Bromo-4-(2-methyl-2-propanyl)benzaldehyde
Molecular Formula:C11H13BrO
Molecular Weight:241.124
HS Code:2913000090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:274.9±28.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.555
PSA:17.07000
Exact Mass:240.014969
LogP:4.14
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-bromo-4-t-butylbenzaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Bromo-4-(2-methyl-2-propanyl)benzaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzaldehyde, 2-bromo-4-(1,1-dimethylethyl)- Use and application,2-Bromo-4-(2-methyl-2-propanyl)benzaldehyde technical grade,usp/ep/jp grade.
Related News: Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). 2-Bromo-4-tert-butylbenzaldehyde manufacturer f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national. 2-Bromo-4-tert-butylbenzaldehyde supplier Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). 2-Bromo-4-tert-butylbenzaldehyde vendor Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). 2-Bromo-4-tert-butylbenzaldehyde factory A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA��s concerns.
